Jim Cramer on Structure Therapeutics: “I Don’t Want to Touch It”

Group 1 - Structure Therapeutics Inc. (NASDAQ:GPCR) is involved in developing oral small-molecule drugs aimed at treating chronic conditions such as obesity and pulmonary fibrosis [1] - The company has a partnership with Roche, which is viewed as a positive aspect, but the stock price is perceived to fully reflect this deal, leading to a cautious stance on investment [1] - Comparatively, Eli Lilly is mentioned as the "gold standard" in the industry, suggesting that GPCR may not be the best investment choice at this time [1] Group 2 - There is a belief that certain AI stocks present greater upside potential and lower downside risk compared to GPCR, indicating a shift in investment focus [2] - The article suggests that there are undervalued AI stocks that could benefit from current economic trends, such as tariffs and onshoring, which may be more attractive to investors [2]